2.1. Patient Population and Design
muscle diseases, cardiovascular disease
MUSCLE DISEASE, CARDIOVASCULAR DISEASE
Patients were eligible based on the following criteria:Inclusion criteria:Age between 40 and 75;LDL-C level between 70 and 190 mg/dL, confirmed in at least two sequential checks conducted within the last six months prior to signing the consent form.Exclusion criteria:Personal history of cardiovascular disease or high risk (≥20%);Triglycerides (TG) ≥ 400 mg/dL;Body Mass Index ≥ 35 kg/mAssumption of lipid-lowering drugs or supplements affecting lipid metabolism within the last three months;Diabetes mellitus;Known severe or uncontrolled thyroid, liver, renal, or muscle diseases.Patients were randomized to omega-3 fatty acids (Participants had a fasting lipid panel, complete metabolic panel, and high-sensitivity After randomization, all patients provided DNA samples for SNP selection and genotyping. Following genotyping, patients exhibiting at least one of the following PPARG gene polymorphisms: rs10865710 (G allele), rs7649970 (T allele), rs1801282 (G allele), and rs3856806 (T allele) were allocated into a separate subgroup [In this study, S.Lab (SOLOWAYS), a pharmaceutical company, contributed solely by manufacturing the omega-3 fatty acid supplements used in the research. S.Lab (SOLOWAYS) did not participate in the design, execution, or financing of the experiment beyond providing the required supplements. The entire study was independently conducted by a research team from the Center for New Medical Technologies and the Scientific Research Laboratory at Triangel Scientific. This arrangement ensured that the study’s outcomes were not influenced by commercial interests, maintaining the integrity and independence of our research.